MedPath

Dietary Supplement With and Without a Probiotic

Not Applicable
Completed
Conditions
Healthy Adult Subjects
Registration Number
NCT04433208
Lead Sponsor
Prolacta Bioscience
Brief Summary

Complex oligosaccharides can alter the gut microbiome by aiding in the growth of certain organisms, and possibly, inhibiting others. The synergy with a probiotic may enhance gastrointestinal colonization.

Detailed Description

The study will evaluate the synergy of the use of a complex oligosaccharide with and without a probiotic on the human microbiome in healthy volunteers. The combination should support general gastrointestinal health.

The study a multi-dose randomized cohort trial using 10 subjects per cohort for a total of 60 healthy adult volunteers ages 18-44.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
62
Inclusion Criteria
  • Healthy adults between the ages of 18-44 years
  • Willingness to complete all study procedures and clinic visits, and provide required samples
  • Provides informed consent
Exclusion Criteria
  • Women who are pregnant or breastfeeding, or intend to become pregnant during the course of this study
  • Subjects with history of lactose intolerance
  • Subjects who are on a PPI regimen
  • Subjects who have taken a probiotic during the previous 30 days, or intends to take a probiotic during the study.
  • Subjects who have taken antibiotics within 120 days
  • Alcohol or drug abuse during the last 12 months, including passing a screen for drugs of abuse at screening
  • Unstable medical condition, in the opinion of the investigator
  • Clinically significant abnormal laboratory test results at screening
  • Participation in a clinical research trial within 30 days prior to screening
  • Unable to give informed consent
  • Any condition which may preclude subject's ability to comply with and complete the study or may pose a risk to the health of the subject

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Evaluation of the Levels of B.Infantis in Stool by Quantitative PCRAll Cohorts - Day 1, 5, 8, 15 and 29; Cohort 5 - additionally Days 33, 36, 43, 50 and 57

qPCR analysis uses primers for species and strain on DNA extracted from stool samples and is reported as genome copies per nanogram of DNA. The higher the value, the greater indication of engraftment of B.infantis signal over time indicating retention of introduced species.

Secondary Outcome Measures
NameTimeMethod
Changes in Concentration of Blood Parameters From Day 1 to Day 15Day 1 - 15

Blood samples are collected and tested for analysis of the levels of cytokines using Luminex-based chemistry to assess for immunology screening and safety monitoring of liver function, renal function, and electrolytes and glucose.

Summary of the Evaluation of the Use of Proton Pump Inhibitors for Protection of B. Infantis Levels in Cohorts 5 and 6 by VisitDay 1, 5, 8, 15, 22, 29, 33, 43, 50, 57

Evaluation of B. infantis levels in Dose Group 5 will be compared to B. infantis levels in Dose Groups 6 using descriptive statistics including geometric means and 95% confidence intervals of the genome copy number per nanogram of DNA (B. infantis copies/ng DNA).

Concentrations (µmol/g) of Lactic Acid in Stool Samples From Day 1 to Day 29Day 1, 8, 15, 29

Descriptive statistics including means and standard deviation of lactate (Cohort 1; 0g HMO + B. infantis, Cohort 2; 18 g HMO, engrafted subjects and not engrafted subjects from Cohorts 5 \& 6 combined; 18g HMO + B.

infantis). Descriptive statistics will not include analytes that were not detected in greater than 50% of samples.

Changes in Concentration of Blood Parameters From Day 1 to Day 15 (Factor VII)Day 1 - 15

Blood samples are collected and tested for analysis of the levels of cytokines using Luminex-based chemistry to assess for immunology screening and safety monitoring of liver function, renal function, and electrolytes and glucose.

Changes in Concentration of Blood Parameters From Day 1 to Day 15 (ICAM-1)Day 1 - 15

Blood samples are collected and tested for analysis of the levels of cytokines using Luminex-based chemistry to assess for immunology screening and safety monitoring of liver function, renal function and electrolytes and glucose.

Trial Locations

Locations (1)

WCCT Global

🇺🇸

Cypress, California, United States

WCCT Global
🇺🇸Cypress, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.